|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-12-30
|
|
pubmed:abstractText |
Schizophrenia afflicts approximately 0.7% of Mexican citizens during their lifetime. This study explored whether the difference in clinical efficacy and safety between atypical antipsychotics and conventional neuroleptics results in decreases in use and cost of medical services in Mexico, offsetting the higher price of atypical antipsychotics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0188-4409
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
572-80
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12505105-Ambulatory Care,
pubmed-meshheading:12505105-Antipsychotic Agents,
pubmed-meshheading:12505105-Benzodiazepines,
pubmed-meshheading:12505105-Brief Psychiatric Rating Scale,
pubmed-meshheading:12505105-Cost-Benefit Analysis,
pubmed-meshheading:12505105-Haloperidol,
pubmed-meshheading:12505105-Hospitalization,
pubmed-meshheading:12505105-Humans,
pubmed-meshheading:12505105-Markov Chains,
pubmed-meshheading:12505105-Mexico,
pubmed-meshheading:12505105-Pirenzepine,
pubmed-meshheading:12505105-Risperidone,
pubmed-meshheading:12505105-Schizophrenia,
pubmed-meshheading:12505105-Sensitivity and Specificity,
pubmed-meshheading:12505105-Software,
pubmed-meshheading:12505105-Time Factors,
pubmed-meshheading:12505105-Treatment Outcome
|
|
pubmed:articleTitle |
A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
|
|
pubmed:affiliation |
Center for Organization and Delivery Studies, Agency for Health Care Policy and Research, Rockville, MD, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
